Last reviewed · How we verify
PRIMAQUINE PHOSPHATE
At a glance
| Generic name | PRIMAQUINE PHOSPHATE |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1952 |
Approved indications
Common side effects
- Nausea
- Vomiting
- Epigastric distress
- Abdominal cramps
- Hemolytic anemia
- Leukopenia
- Decreased hemoglobin
- Methemoglobinemia
- Rash
- Pruritus
- Dizziness
Serious adverse events
- Severe hemolytic anemia
- Fatal hemolytic anemia
- Severe methemoglobinemia
- Cardiac arrhythmia
- QT interval prolongation
Key clinical trials
- Serological Testing and Treatment for Plasmodium Vivax Malaria: a Trial in Ethiopia and Madagascar (PHASE3)
- Radical Cure (RC) With Tafenoquine or Primaquine After Semi-quantitative G6PD Testing: A Feasibility Study in Peru
- Postpartum 8-aminoquinoline Breast Milk Study (PHASE2, PHASE3)
- An Ultra-short Course of Primaquine for the Radical Cure of Vivax Malaria (PHASE3)
- Primaquine for Vivax Malaria in G6PD Intermediate and Deficient Cases. (PHASE4)
- Assessing the Feasibility of Combining Dihydroartemisinin Piperaquine and Primaquine for Malaria Mass Drug Administration in High Endemic Communities in the Eastern Region of Ghana (NA)
- Positioning Second-line Therapies for Pneumocystis Jirovecii Pneumonia (PCP Alternatives) (PHASE4)
- Short Course Primaquine for the Radical Cure of P. Vivax Malaria - Indonesia (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PRIMAQUINE PHOSPHATE CI brief — competitive landscape report
- PRIMAQUINE PHOSPHATE updates RSS · CI watch RSS